JSPR · Jasper Therapeutics
Jasper Therapeutics, Inc., a clinical stage biotechnology company, focuses on the design and development of therapies to treat immune-mediated diseases. Its products in various stages of development include KP-104, a dual-complement inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) which is in Phase 2; Briquilimab is an anti-KIT antibody, which has demonstrated clinical results as a conditioning agent for stem cell transplant and mast cell mediated diseases, such as chronic urticarias and allergic asthma; and KP-701, a novel, dual-acting anti-CD79BxCD32B monoclonal antibody (mAb) for autoantibody-mediated disorders. The company is headquartered in Redwood City, California.
Market Cap
11.48M
52 Wk Range
$9.25 - $72.60
Previous Close
$10.34
Open
$10.67
Volume
19,298
Day Range
$10.66 - $11.86
Enterprise Value
6.354M
Cash
135.3M
Avg Qtr Burn
-5.497M
Insider Ownership
2.55%
Institutional Own.
56.46%
Qtr Updated
Sep 30th 2026
